Literature DB >> 6408170

Induction of phenotypic differentiation, interleukin 2 production, and PHA responsiveness of "immature" human thymocytes by interleukin 1 and phorbol ester.

J E de Vries, F A Vyth-Dreese, C G Figdor, H Spits, J M Leemans, W S Bont.   

Abstract

Small human thymocytes (ST) representing 70% of the thymocytes were isolated according to size by centrifugal elutriation. Although these ST contained approximately 30% PNA-cells, they failed to respond to lectins, indicating the existence of a PNA-ST subset that can be considered to belong to the "immature" thymocyte population. The ST were induced to proliferate if, in addition to PHA, IL 1-containing supernatants of highly purified monocyte cultures or 12-O-tetradecanoyl-phorbol-13-acetate (TPA) were present. The incubation of the ST for 90 hr with TPA or IL 1 in the absence of PHA resulted in a strong reduction in the percentage of cells reacting with the immature thymocyte markers TdT and PNA. In addition, the OKT6+ cells were partially reduced after incubation with IL 1. Concomitantly, an increase in the percentage of cells reacting with the mature T cell markers OKT1 and OKT3 was observed, whereas HLA antigens became strongly expressed on all ST. Although IL 1 or TPA were unable to induce proliferation of the ST, these substances induced IL 2 production by these cells. These shifts to cells with more "mature" phenotypes that are able to produce IL 2 were not observed if the ST were incubated with PHA or culture medium only. The responder capacity of the ST to PHA plus TPA was not significantly affected by the depletion of the more "mature" OKT3+ and OKT1+ cells. In addition, in this situation OKT1+, OKT3+, OKT6- cells were found to be generated from OKT1-, OKT3-, OKT6+ cells. Therefore, it could be excluded that the proliferative responses were due to a selective expansion of a preexisting mature T cell population. Our results indicate that TPA mimics IL 1 in the induction of differentiation of the ST to a stage in which subpopulations of these cells are able to produce IL 2 and to respond to PHA. Because only the proliferating ST were found to react with a monoclonal antibody, which is thought to be directed at the IL 2 receptor (anti-Tac), our data suggest that PHA is required for the induction of expression of receptors for IL 2 in those ST subpopulations that are able to proliferate in the presence of IL 2 generated in situ.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408170

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  The Toll-like receptors: analysis by forward genetic methods.

Authors:  Bruce Beutler
Journal:  Immunogenetics       Date:  2005-07       Impact factor: 2.846

2.  Expression of early activation antigen (CD69) during human thymic development.

Authors:  L K Jung; B F Haynes; S Nakamura; S Pahwa; S M Fu
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

3.  Induction of interleukin 2 receptors on immature human thymocytes and co-expression of T3 and T6 antigens.

Authors:  G H Reem; K L Davis; S Carding
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

Review 4.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

5.  Unfractionated human thymocytes have a lower proliferative capacity than CD3-4-8- ones but have a similar capacity for expression of interleukin 2 receptors and production of interleukin 2.

Authors:  J Vives; J Solé; B Suarez
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Mature T-lineage leukemia with growth factor-induced multilineage differentiation.

Authors:  F Griesinger; D C Arthur; R Brunning; J L Parkin; A C Ochoa; W J Miller; C W Wilkowski; J M Greenberg; C Hurvitz; J H Kersey
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.